Patents by Inventor Edward J. Rebar

Edward J. Rebar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES
    Publication number: 20210317430
    Abstract: Described herein are engineered nucleases specific for PD1 gene target sites, the nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity for PD1 gene target sites is increased.
    Type: Application
    Filed: September 18, 2019
    Publication date: October 14, 2021
    Inventors: Jeffrey C. MILLER, Edward J. REBAR, Lei ZHANG
  • Htt repressors and uses thereof
    Patent number: 11123443
    Abstract: Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: September 21, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Steven Froelich, Jeffrey C. Miller, David Paschon, Edward J. Rebar, Bryan Zeitler, H. Steve Zhang
  • METHODS AND COMPOSITIONS FOR GENOME ENGINEERING
    Publication number: 20210188926
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.
    Type: Application
    Filed: March 1, 2021
    Publication date: June 24, 2021
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar, Thomas Wechsler, Lei Zhang
  • METHODS AND COMPOSITIONS FOR REGULATION OF TRANSGENE EXPRESSION
    Publication number: 20210189405
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Application
    Filed: March 3, 2021
    Publication date: June 24, 2021
    Inventor: Edward J. Rebar
  • Method for the treatment of lysosomal storage diseases
    Patent number: 11040115
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: June 22, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Methods and compositions for regulation of transgene expression
    Patent number: 10975375
    Abstract: Nucleases and methods of using these nucleases for expressing a transgene from a safe harbor locus in a secretory tissue, and clones and animals derived therefrom.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: April 13, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Engineered target specific nucleases
    Patent number: 10975393
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 13, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Methods and compositions for genome engineering
    Patent number: 10968261
    Abstract: Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: April 6, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar, Thomas Wechsler, Lei Zhang
  • METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE
    Publication number: 20210060124
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 4, 2021
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS
    Publication number: 20210054046
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 25, 2021
    Inventors: Trevor Collingwood, Laurence J.N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • ENGINEERED TARGET SPECIFIC NUCLEASES
    Publication number: 20210024957
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 28, 2021
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • ENGINEERED TARGET SPECIFIC NUCLEASES
    Publication number: 20210024958
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 28, 2021
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • Methods and compositions for modification of a HLA locus
    Patent number: 10858416
    Abstract: Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: December 8, 2020
    Assignees: Sangamo Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Trevor Collingwood, Laurence J. N. Cooper, Philip D. Gregory, Michael C. Holmes, Jeffrey C. Miller, Edward J. Rebar, Andreas Reik, Fyodor Urnov
  • Methods and compositions for treating Huntington's disease
    Patent number: 10857203
    Abstract: Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: December 8, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
  • ENGINEERED TARGET SPECIFIC NUCLEASES
    Publication number: 20200340016
    Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.
    Type: Application
    Filed: July 14, 2020
    Publication date: October 29, 2020
    Inventors: Jeffrey C. Miller, Edward J. Rebar
  • COMPOSITIONS FOR LINKING DNA-BINDING DOMAINS AND CLEAVAGE DOMAINS
    Publication number: 20200318087
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • Compositions for linking DNA-binding domains and cleavage domains
    Patent number: 10724020
    Abstract: Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: July 28, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Jeffrey C. Miller, David Paschon, Edward J. Rebar
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES
    Publication number: 20200231989
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Application
    Filed: April 7, 2020
    Publication date: July 23, 2020
    Inventor: Edward J. Rebar
  • Method of treating mucopolysaccharidosis type I or II
    Patent number: 10648001
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Methods and compositions for treating trinucleotide repeat disorders
    Patent number: 10646543
    Abstract: Disclosed herein are methods and compositions for treating trinucleotide repeat disorders.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Philip D. Gregory, Edward J. Rebar, H. Steve Zhang